26 March 2019 | News
EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena's single-cell printers
A life science start-up Cytena GmbH successfully completes another financing round. In total, two private investors and High-Tech Gründerfonds (HTGF) are investing another 3 million euros in the company. The new capital will be used to continue developing its single-cell printer lab technology, expand sales activities and tap into the potential of new applications more quickly.
The analysis of individual biological cells has rapidly gained in importance in recent years. Single cells are used in the development of modern drugs, so-called biopharmaceuticals, as well as in cancer and stem cell research. The Cytena family of single-cell printers consists of laboratory devices for handling and sorting individual viable cells.
These instruments are innovative tools for the life sciences and make a long-term contribution to the development and manufacturing of new drugs